CUV9900 is an alpha-Melanocyte Stimulating Hormone (alpha-MSH) analogue which the company intends will complement Clinuvel's lead product SCENESSE® (afamelanotide 16mg). It belongs to the same family of molecules, known as melanocortins, as afamelanotide.
Recent research has shown that CUV9900 is a potent skin protectant. Clinuvel intends to launch CUV9900 in various new formulations. Formulation work has commenced and Clinuvel expects the first formulations to be available for clinical testing after the commercialisation of its lead product.